Europe Blood Collection Devices Market Outlook, 2031
The Europe Blood Collection Devices Market is segmented into By Product Type (Blood Collection Tubes, Needles & Syringes, Blood Bags, Blood Collection Systems/Monitors, Lancets, Others); By End-User (Hospitals and ASCs, Diagnostics and Pathology Laboratories, Blood Banks, Others); By Application (Diagnostic Application, Therapeutic Application); By Method (Manual, Automated).
- Bonafide Research
- 02-09-2026
- Pages : 101
- Figures : 9
- Tables : 33
- Region : Europe
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The Europe Blood Collection Devices Market was valued at more than 2.43 Billion in 2025, driven by the increasing prevalence of chronic diseases.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 2.43 Billion
- Largest Market Germany
- Fastest Market United Kingdom
- Format
Featured Companies
- 1. Medline Industries, LP
- 2. Beckton Dickinson
- 3. Cardinal Health, Inc.
- 4. McKesson Corporation
- 5. Terumo Corporation
- 6. Nipro Corporation
- More...
Blood Collection Devices Market Analysis
The Europe blood collection devices market encompasses the manufacturing, distribution, and utilization of medical equipment such as needles, syringes, blood collection tubes, lancets, and blood bags designed to safely extract blood samples for diagnostic, therapeutic, and transfusion purposes. This market is vital to modern European healthcare, holding immense importance for routine clinical diagnostics, management of chronic conditions like diabetes and cardiovascular disorders, and ensuring safe blood bank operations. The market's primary growth drivers include a rapidly aging European population, a rising prevalence of lifestyle and infectious diseases, and an escalating emphasis on early disease detection and preventive healthcare. Furthermore, strict regulatory standards under the European Union’s In Vitro Diagnostic Regulation (IVDR) heavily influence product development, pushing manufacturers toward safer, user-friendly, and automated pre-analytical systems. Key industry participants and stakeholders coordinate through prominent regional bodies such as MedTech Europe, the European trade association representing the medical technology industry, which actively engages with policymakers on regulatory compliance, innovation adoption, and supply chain resilience. Activities within this sector heavily revolve around research and development for minimally invasive micro-sampling tools, expanding localized production capacities, and implementing sustainable biomedical waste solutions to meet stringent European environmental and safety frameworks. Ultimately, these technological and regulatory shifts position the European sector for sustained, innovation-driven expansion. Market players continuously refine their supply chains to support decentralized testing and patient-centric healthcare models across member states. According to the research report, "Europe Blood Collection Devices Market Outlook, 2031," published by Bonafide Research, the Europe Blood Collection Devices Market was valued at more than 2.43 Billion in 2025. The European blood collection devices market is a well-established regional sector led by key international and domestic players, including Becton Dickinson (BD), Greiner Bio-One, Sarstedt AG & Co. KG, Terumo Europe, and Fresenius Kabi. Accounting for roughly 25% to 27% of the global market share, Europe’s high volume of blood testing is anchored by universal public healthcare systems and a rapidly aging population facing chronic diseases. Industry developments focus heavily on clinical sustainability, patient comfort, and workflow automation. Notable advances include Greiner Bio-One’s expansion of eco-friendly, recyclable vacuum blood collection tubes designed to minimize medical waste under stringent European Union environmental standards, alongside Sarstedt’s refined capillary micro-sampling lines that reduce venipuncture pain for pediatric and geriatric patient groups. Massive opportunities exist in capillary blood collection, decentralized liquid biopsy testing for early-stage oncology, and the integration of RFID tracking within evacuated tube systems to streamline pre-analytical laboratory workflows. The European supply chain begins with precision component suppliers sourcing medical-grade polymers, glass, anti-coagulants, and specialized stainless steel. These raw materials flow to local automated manufacturing hubs in Germany, Austria, and France, where strict EU Medical Device Regulation (MDR) compliance governs production. Products move through centralized national distribution channels to reach hospitals, diagnostic reference labs, and blood banks. However, strict regulatory compliance timelines under MDR framework, rising energy costs in European manufacturing plants, and reliance on imported raw materials expose the regional supply chain to logistical bottlenecks and margin pressures.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Universal healthcare systems, high diagnostic screening rates, and aging demographics: Europe’s well-funded public healthcare systems (such as the UK’s NHS and national health insurance systems in Germany and France) strongly emphasize preventive care and routine diagnostic screening. Coupled with a rapidly aging demographic, the region faces a high prevalence of chronic conditions, including cardiovascular diseases, type-2 diabetes, and oncology indications. Because national health frameworks cover routine lab work, clinical diagnostic volume is consistently high across European public and private laboratories. This creates a steady, high-volume baseline demand for essential phlebotomy consumables like evacuated vacuum tubes (serum, EDTA, coagulation), safety needles, and lancets across hospitals and outpatient clinics.• Strict workplace biosafety standards and regulatory mandates for infection control: European directives notably EU Directive 2010/32/EU mandate the prevention of sharps injuries in the hospital and healthcare sector. The strict enforcement of safety standards across EU member states compels medical institutions to utilize advanced, safety-engineered blood collection devices. Facilities are legally obligated to deploy needles with integrated safety shields, active/passive retraction systems, and closed collection sets to protect phlebotomists, nurses, and lab personnel from accidental needle-sticks and blood-borne contamination. This regulatory climate pushes the market toward high-value, compliant safety products, driving sustained revenue expansion across Western and Central Europe.
Market Challenges
• Regulatory friction and compliance costs under EU medical device regulation (MDR): The ongoing transition to the EU Medical Device Regulation (MDR 2017/745) presents a significant operational hurdle for device manufacturers. The MDR framework imposes far stricter clinical evaluation rules, continuous post-market surveillance, and comprehensive technical documentation requirements compared to legacy Directive guidelines. As a result, blood collection device companies face extended approval timelines, high recertification costs, and complex regulatory submission backlogs.• Manufacturing cost inflation, energy volatility, and supply chain vulnerabilities: European device manufacturers face notable cost volatility concerning essential raw materials such as medical-grade polymers, glass, synthetic rubber, and stainless steel alongside fluctuating industrial energy prices. Because European medical device packaging relies on sterile, high-purity plastic resins, regional energy and chemical supply disruptions impact domestic manufacturing facilities (particularly in Germany, Austria, and France).
Market Trends
• Emphasis on sustainable, eco-friendly blood collection materials: European environmental legislation and green-procurement initiatives within healthcare systems (e.g., NHS Net Zero commitments) are accelerating demand for eco-friendly medical consumables. Manufacturers are actively developing bio-based polymers, thinner-walled plastic collection tubes, and recyclable packaging materials to minimize plastic waste and lower the carbon footprint of high-volume phlebotomy.• Integration of automation, RFID sample tracking, and liquid biopsy compatibility: To overcome phlebotomy labor bottlenecks and streamline pre-analytical laboratory workflows, European diagnostic centers are rapidly adopting smart, automated collection infrastructure. The market is seeing increased adoption of RFID-tagged vacuum tubes and 2D barcode identification systems that automatically log draw time, specimen volume, and temperature exposure into central hospital databases to eliminate diagnostic errors.
Blood Collection Devices Segmentation
| By Product Type | Blood Collection Tubes | |
| Needles & Syringes | ||
| Blood Bags | ||
| Blood Collection Systems/Monitors | ||
| Lancets | ||
| Others | ||
| By End-User | Hospitals and ASCs | |
| Diagnostics and Pathology Laboratories | ||
| Blood Banks | ||
| Others | ||
| By Application | Diagnostic Application | |
| Therapeutic Application | ||
| By Method | Manual | |
| Automated | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
Lancets are the fastest-growing product segment because the expansion of self-testing, diabetes monitoring, and decentralized blood sampling is increasing the need for convenient, minimally invasive capillary blood collection. Lancets are becoming increasingly important in Europe because they enable quick capillary blood sampling with limited discomfort and can be used in both professional healthcare environments and patient-managed testing. Their strongest practical advantage is that they require only a small puncture of the fingertip or another suitable site to obtain a blood drop, making them particularly useful for tests that do not require a conventional venous specimen. Diabetes management is a major real-world application because people who monitor blood glucose frequently may need repeated finger-prick sampling as part of their daily care routine. The European health system has a substantial diabetes burden, and the International Diabetes Federation identifies Europe as one of the major global regions affected by diabetes, creating a continuing need for accessible glucose-monitoring practices. Lancets also support other point-of-care procedures where small blood volumes are sufficient, including certain hemoglobin, cholesterol, coagulation, and infectious-disease assessments. Their disposable design is another important factor because individual-use lancets can help reduce cross-contamination risks when appropriate infection-control procedures are followed. Modern safety lancets have also been developed with features such as automatic retraction or shielding, which are designed to reduce accidental needlestick exposure for healthcare workers and patients. This aligns with European occupational-safety priorities surrounding sharps injuries. The shift toward decentralized healthcare is further supporting their practical relevance. Blood testing is increasingly performed outside traditional central laboratories, including pharmacies, primary-care settings, community services, and home environments. A lancet can be incorporated into compact testing systems that require only a small blood sample, allowing results to be generated closer to the patient. Europe is also experiencing greater emphasis on chronic-disease management, preventive healthcare, and patient participation in monitoring. The “others” end-user segment is growing fastest because blood collection is increasingly being performed across decentralized settings such as physician practices, pharmacies, home-care environments, community facilities, and specialized outpatient services. The expansion of blood collection beyond conventional hospitals and large diagnostic laboratories is changing where and how specimens are obtained in Europe. The “others” category can include a diverse group of users such as physician offices, specialty clinics, pharmacies, home-care providers, nursing facilities, occupational-health services, research organizations, and other decentralized healthcare locations, depending on the market classification. These settings are gaining importance because healthcare delivery is progressively moving closer to patients, particularly for chronic conditions that require repeated monitoring rather than one-time hospital intervention. European healthcare systems increasingly emphasize primary care, community-based services, prevention, and management of long-term diseases, creating more opportunities for blood specimens to be collected outside major hospitals. Primary-care professionals may require blood samples for routine monitoring of conditions such as diabetes, anemia, kidney disease, lipid disorders, and thyroid abnormalities. Home-care services can also support patients who have difficulty traveling to hospitals or centralized laboratories, while residential and long-term care facilities may need access to testing for older adults with multiple chronic conditions. Pharmacies and community-based healthcare providers are also increasingly involved in screening and point-of-care testing in several European countries, although the exact services and regulatory frameworks differ between nations. The development of decentralized testing is particularly relevant because modern blood collection devices can be designed for small-volume sampling and rapid handling. Capillary collection devices, micro-sampling technologies, safety needles, and compact blood collection systems can simplify specimen acquisition in locations where full laboratory infrastructure is unavailable. In addition, Europe's aging population creates greater demand for accessible healthcare services because older individuals are more likely to require regular monitoring and may have mobility limitations. The European Commission has highlighted demographic aging as a major structural issue for European healthcare systems, reinforcing the need for care models that can support patients outside traditional acute-care facilities. Therapeutic applications are the fastest-growing application segment because blood collection is increasingly integrated with treatment monitoring, medication management, chronic-disease control, and procedures in which laboratory measurements directly guide therapy. Blood collection devices have traditionally been strongly associated with diagnosis, but their role does not end once a disease has been identified. Blood specimens are also essential for determining whether treatment is working, whether a medication is producing the intended physiological response, and whether therapy is creating adverse effects that require intervention. This makes therapeutic applications an increasingly important area for blood collection in European healthcare. Patients receiving long-term treatments for conditions such as diabetes, kidney disease, cardiovascular disorders, autoimmune diseases, cancer, and hematological disorders may undergo repeated blood testing during treatment. These tests can help clinicians evaluate biochemical parameters, blood-cell counts, organ function, coagulation status, drug-related effects, and other indicators that influence treatment decisions. Therapeutic drug monitoring provides a particularly clear example because measurements of selected medicines in blood can help clinicians adjust dosing to achieve an appropriate therapeutic effect while limiting toxicity. The European Medicines Agency recognizes therapeutic drug monitoring as relevant for medicines where monitoring concentrations or treatment response can support individualized dosing decisions. Blood collection is also important during therapies that can affect bone marrow, liver, kidneys, or coagulation. For example, patients receiving certain oncology treatments may require repeated blood counts and biochemical testing before or during treatment to determine whether therapy can safely continue. Similarly, anticoagulation management may involve laboratory assessment in selected clinical circumstances, while patients undergoing dialysis require regular blood-based monitoring as part of their treatment pathway. Chronic disease management further increases the frequency of therapeutic monitoring because treatment effectiveness may need to be assessed over extended periods rather than during a single clinical encounter. Europe's emphasis on personalized and integrated healthcare also encourages treatment decisions based on patient-specific laboratory information rather than relying solely on symptoms. Automated blood collection is the fastest-growing method segment because healthcare providers are increasingly adopting technologies that improve collection consistency, reduce operator-dependent variability, and support safer and more standardized specimen acquisition. Automation is becoming more relevant to blood collection as healthcare systems seek to improve workflow efficiency while addressing workforce pressures and the need for consistent specimen quality. Traditional venipuncture remains deeply established, but automated and technology-assisted collection systems can introduce greater standardization into a procedure that is normally dependent on the skill, experience, and technique of an individual operator. This is particularly valuable in environments where large numbers of specimens must be collected or where difficult venous access creates repeated challenges. Automated systems can incorporate features intended to assist with vein identification, needle positioning, blood withdrawal, or other parts of the collection process, depending on the technology. Robotic blood-draw technologies are an example of this direction. In the United States, the FDA has authorized robotic blood-draw technology, demonstrating that automated approaches have progressed beyond laboratory automation and into the actual specimen-collection stage. Europe is also experiencing strong investment in healthcare automation as providers attempt to address staff shortages, improve productivity, and maintain consistent quality. The European Commission has identified digital transformation and the adoption of advanced technologies as important components of modernizing healthcare systems. Automation can potentially reduce the number of repeated attempts required for some patients, which may improve the experience for individuals with difficult-to-access veins. It may also help standardize the amount and timing of blood withdrawal and reduce certain forms of operator-related variation. Another important consideration is occupational safety. Needlestick injuries remain an established occupational hazard for healthcare workers, and automated or safety-oriented collection technologies can incorporate mechanisms designed to reduce exposure to sharps. Automated systems may also integrate with digital identification and documentation processes, creating opportunities for more traceable specimen workflows. Their usefulness is especially relevant in high-throughput environments where healthcare personnel spend considerable time performing repetitive collection procedures.
to Download this information in a PDF
Blood Collection Devices Market Regional Insights
The UK is the fastest-growing regional segment because its advanced healthcare infrastructure, extensive laboratory network, strong adoption of digital health technologies, and growing emphasis on decentralized and efficient diagnostic services support increasing use of modern blood collection solutions. The United Kingdom provides a strong environment for the adoption of blood collection devices because blood sampling is deeply integrated into its healthcare system, particularly through the National Health Service and its extensive network of hospitals, general practices, community services, and diagnostic laboratories. The NHS performs a very large volume of clinical investigations across primary, secondary, and community care, making specimen collection an essential part of everyday healthcare delivery. Blood tests are routinely used for monitoring chronic conditions, assessing symptoms, checking organ function, managing medications, preparing patients for procedures, and evaluating treatment responses. The UK's growing focus on moving suitable care away from hospitals and toward community and primary-care environments also creates opportunities for decentralized blood collection. General practices and community services can perform or arrange testing closer to patients, reducing the need for hospital visits when clinically appropriate. This approach is particularly relevant for an aging population and individuals living with long-term conditions who require regular monitoring. The UK also has a well-developed pathology infrastructure, with NHS pathology services supporting a wide range of hematology, clinical chemistry, microbiology, immunology, and other laboratory disciplines. Standardized specimen collection is therefore important because blood samples must reach laboratories in a condition suitable for accurate analysis. The NHS has also pursued digital transformation and interoperability initiatives designed to connect clinical information and diagnostic services more effectively.
to Download this information in a PDF
Companies Mentioned
- Medline Industries, LP
- Beckton Dickinson
- Cardinal Health, Inc.
- McKesson Corporation
- Terumo Corporation
- Nipro Corporation
- Thermo Fisher Scientific Inc
- Sarstedt AG & Co. KG
- Greiner Holding AG
- Fresenius Kabi AG
- Haemonetics Corporation
- Sol-Millennium Medical Group
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. Europe Blood Collection Devices Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By By Product Type
- 6.4. Market Size and Forecast, By By End-User
- 6.5. Market Size and Forecast, By By Application
- 6.6. Market Size and Forecast, By By Method
- 6.7. Germany Blood Collection Devices Market Outlook
- 6.7.1. Market Size by Value
- 6.7.2. Market Size and Forecast By By Product Type
- 6.7.3. Market Size and Forecast By By End-User
- 6.7.4. Market Size and Forecast By By Application
- 6.7.5. Market Size and Forecast By By Method
- 6.8. United Kingdom (UK) Blood Collection Devices Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By By Product Type
- 6.8.3. Market Size and Forecast By By End-User
- 6.8.4. Market Size and Forecast By By Application
- 6.8.5. Market Size and Forecast By By Method
- 6.9. France Blood Collection Devices Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By By Product Type
- 6.9.3. Market Size and Forecast By By End-User
- 6.9.4. Market Size and Forecast By By Application
- 6.9.5. Market Size and Forecast By By Method
- 6.10. Italy Blood Collection Devices Market Outlook
- 6.10.1. Market Size by Value
- 6.10.2. Market Size and Forecast By By Product Type
- 6.10.3. Market Size and Forecast By By End-User
- 6.10.4. Market Size and Forecast By By Application
- 6.10.5. Market Size and Forecast By By Method
- 6.11. Spain Blood Collection Devices Market Outlook
- 6.11.1. Market Size by Value
- 6.11.2. Market Size and Forecast By By Product Type
- 6.11.3. Market Size and Forecast By By End-User
- 6.11.4. Market Size and Forecast By By Application
- 6.11.5. Market Size and Forecast By By Method
- 6.12. Russia Blood Collection Devices Market Outlook
- 6.12.1. Market Size by Value
- 6.12.2. Market Size and Forecast By By Product Type
- 6.12.3. Market Size and Forecast By By End-User
- 6.12.4. Market Size and Forecast By By Application
- 6.12.5. Market Size and Forecast By By Method
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Porter's Five Forces
- 7.4. Company Profile
- 7.4.1. BD
- 7.4.1.1. Company Snapshot
- 7.4.1.2. Company Overview
- 7.4.1.3. Financial Highlights
- 7.4.1.4. Geographic Insights
- 7.4.1.5. Business Segment & Performance
- 7.4.1.6. Product Portfolio
- 7.4.1.7. Key Executives
- 7.4.1.8. Strategic Moves & Developments
- 7.4.2. Terumo Corporation
- 7.4.3. Cardinal Health
- 7.4.4. Greiner Bio-One International GmbH
- 7.4.5. Fresenius Kabi AG
- 7.4.6. Haemonetics Corporation
- 7.4.7. McKesson Corporation
- 7.4.8. Medline Industries LP
- 7.4.9. Nipro Corporation
- 7.4.10. Sarstedt AG & Co. KG
- 7.4.11. Thermo Fisher Scientific Inc.
- 7.4.12. Sol-Millennium Medical Group
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 10. Disclaimer
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Europe Blood Collection Devices Market Size and Forecast, By By Product Type (2020 to 2031F) (In USD Billion)
Table 6: Europe Blood Collection Devices Market Size and Forecast, By By End-User (2020 to 2031F) (In USD Billion)
Table 7: Europe Blood Collection Devices Market Size and Forecast, By By Application (2020 to 2031F) (In USD Billion)
Table 8: Europe Blood Collection Devices Market Size and Forecast, By By Method (2020 to 2031F) (In USD Billion)
Table 9: Germany Blood Collection Devices Market Size and Forecast By By Product Type (2020 to 2031F) (In USD Billion)
Table 10: Germany Blood Collection Devices Market Size and Forecast By By End-User (2020 to 2031F) (In USD Billion)
Table 11: Germany Blood Collection Devices Market Size and Forecast By By Application (2020 to 2031F) (In USD Billion)
Table 12: Germany Blood Collection Devices Market Size and Forecast By By Method (2020 to 2031F) (In USD Billion)
Table 13: United Kingdom (UK) Blood Collection Devices Market Size and Forecast By By Product Type (2020 to 2031F) (In USD Billion)
Table 14: United Kingdom (UK) Blood Collection Devices Market Size and Forecast By By End-User (2020 to 2031F) (In USD Billion)
Table 15: United Kingdom (UK) Blood Collection Devices Market Size and Forecast By By Application (2020 to 2031F) (In USD Billion)
Table 16: United Kingdom (UK) Blood Collection Devices Market Size and Forecast By By Method (2020 to 2031F) (In USD Billion)
Table 17: France Blood Collection Devices Market Size and Forecast By By Product Type (2020 to 2031F) (In USD Billion)
Table 18: France Blood Collection Devices Market Size and Forecast By By End-User (2020 to 2031F) (In USD Billion)
Table 19: France Blood Collection Devices Market Size and Forecast By By Application (2020 to 2031F) (In USD Billion)
Table 20: France Blood Collection Devices Market Size and Forecast By By Method (2020 to 2031F) (In USD Billion)
Table 21: Italy Blood Collection Devices Market Size and Forecast By By Product Type (2020 to 2031F) (In USD Billion)
Table 22: Italy Blood Collection Devices Market Size and Forecast By By End-User (2020 to 2031F) (In USD Billion)
Table 23: Italy Blood Collection Devices Market Size and Forecast By By Application (2020 to 2031F) (In USD Billion)
Table 24: Italy Blood Collection Devices Market Size and Forecast By By Method (2020 to 2031F) (In USD Billion)
Table 25: Spain Blood Collection Devices Market Size and Forecast By By Product Type (2020 to 2031F) (In USD Billion)
Table 26: Spain Blood Collection Devices Market Size and Forecast By By End-User (2020 to 2031F) (In USD Billion)
Table 27: Spain Blood Collection Devices Market Size and Forecast By By Application (2020 to 2031F) (In USD Billion)
Table 28: Spain Blood Collection Devices Market Size and Forecast By By Method (2020 to 2031F) (In USD Billion)
Table 29: Russia Blood Collection Devices Market Size and Forecast By By Product Type (2020 to 2031F) (In USD Billion)
Table 30: Russia Blood Collection Devices Market Size and Forecast By By End-User (2020 to 2031F) (In USD Billion)
Table 31: Russia Blood Collection Devices Market Size and Forecast By By Application (2020 to 2031F) (In USD Billion)
Table 32: Russia Blood Collection Devices Market Size and Forecast By By Method (2020 to 2031F) (In USD Billion)
Table 33: Competitive Dashboard of top 5 players, 2025
Figure 2: Europe Blood Collection Devices Market Share By Country (2025)
Figure 3: Germany Blood Collection Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: United Kingdom (UK) Blood Collection Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: France Blood Collection Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Italy Blood Collection Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 7: Spain Blood Collection Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 8: Russia Blood Collection Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 9: Porter's Five Forces of Global Blood Collection Devices Market
Blood Collection Devices Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (02 September, 2026)
- Notify To Team (02 September, 2026)
- Report updation (03 September, 2026)
- Report Quality Check (03 September, 2026)
- Report Dispatch (04 September, 2026)
- Hard Copy
Recently Viewed Products
Europe Blood Collection Devices Market Outlook, 2031
We are friendly and approachable, give us a call.